相关临床试验
177
10 进行中
药物批准
47
批准总数
监管机构
2
监管机构数
成立时间
N/A
进行中（未招募）
4
2.3%
Approved For Marketing
1
0.6%
已完成
106
59.9%
Enrolling By Invitation
2
1.1%
尚未招募
4
2.3%
招募中
17
9.6%
终止
30
16.9%
Unknown
4
2.3%
撤回
9
5.1%
- Amneal received FDA approval for four additional generic iohexol injection vial presentations, including 350 mg iodine/mL in 50 mL, 75 mL, and 100 mL vials, and 300 mg iodine/mL in a 50 mL vial. - The newly approved products are the first generic versions referencing OMNIPAQUE across these strengths and vial presentations, with launch expected in Q3 2026. - The expanded portfolio is expected to address the majority of U.S. market demand for iohexol injection, which totaled approximately $706 million in annual sales per IQVIA data. - Iohexol is an iodinated radiographic contrast agent indicated for diagnostic imaging in adults and pediatric patients aged two weeks and older across multiple routes of administration.
- GE HealthCare and Mayo Clinic announced the MI-BET research collaboration to evaluate whether imaging and biomarker insights can personalize radioligand therapy for advanced prostate cancer patients. - The study challenges the conventional fixed-cycle RLT approach by using StarGuide SPECT/CT and MIM LesionID Pro to track tumor response and guide adaptive treatment decisions. - Mayo Clinic is the first U.S. site to investigate GE HealthCare's next-generation StarGuide GX SPECT/CT technology, which aims to improve tumor assessment precision and reduce scan times. - The global theranostics market was valued at $10.29 billion in 2025 and is projected to reach $31.38 billion by 2035, growing at a CAGR of 11.8%.
- The global AI-enabled imaging modalities market is projected to grow from USD 3.62 billion in 2025 to USD 15.16 billion by 2035 at a 15.9% CAGR, according to InsightAce Analytic. - Hospitals represented the largest market share in 2025, fueled by rising adoption of AI-based solutions to enhance diagnostic accuracy and workflow efficiency. - Deep learning technology is expected to grow at the highest rate, enabling precise abnormality detection across CT, MRI, mammography, ultrasound, and X-ray modalities. - North America led the market in 2025 due to advanced healthcare infrastructure, high AI penetration, and substantial investment in imaging technology development.
- The global bone densitometers market is projected to grow from USD 391.3 million in 2026 to USD 584.8 million by 2036 at a 4.1% CAGR, according to FMI Research. - DXA systems remain the clinical gold standard, accounting for 63.0% of total market demand in 2026, while hospitals dominate end-user share at 56.0%. - Growth is increasingly driven by value-based healthcare adoption, preventive osteoporosis screening, and hospital modernization initiatives rather than new installation volume alone. - Procurement strategies are shifting toward enterprise imaging integration, with hospitals prioritizing interoperability, cybersecurity, predictive maintenance, and long-term lifecycle value over hardware specifications.
- Radiation oncology is shifting from a focus on geometric precision to incorporating biological insight, imaging biomarkers, and AI for more individualized treatment. - Quantitative imaging biomarkers extracted from routine CT, MRI, and PET scans show potential to predict toxicity, response, and outcomes without additional testing costs. - Hidden biological variables such as hypoxia, DNA damage response, and sex-based differences remain underutilized, risking treatment inequity in precision radiotherapy. - Tumor heterogeneity—both within single lesions and among multiple metastases—demands combined systemic and local therapy approaches guided by spatio-temporal quantitative imaging.
- Quanterix Corporation has appointed Jim Gute as Chief Commercial Officer to lead a re-acceleration of growth within the company's commercial operations. - Gute brings 20 years of senior commercial leadership experience from GE Healthcare and Exact Sciences, where he most recently served as SVP and Commercial Manager, General Screening. - The appointment comes at a pivotal time as Quanterix prepares to expand its diagnostics business, with particular focus on the Alzheimer's disease market. - CEO Everett Cunningham stated Gute's expertise will help build upon the company's large installed base and increase new customers for its ultra-sensitive biomarker testing and spatial analysis offerings.
- The global wearable cardiac monitoring devices market was valued at USD 2.9 billion in 2025 and is projected to reach USD 10.3 billion by 2036, expanding at a CAGR of 12.1%. - The electrocardiography (ECG) technology segment dominated the market in 2025, accounting for approximately 62.1% of total revenue, driven by its clinical accuracy in detecting arrhythmias and atrial fibrillation. - North America held the largest regional share at 41.2% in 2025, supported by advanced healthcare infrastructure and growing adoption of remote patient monitoring solutions. - Rising prevalence of cardiovascular diseases and cardiac arrhythmias, coupled with growing demand for continuous, real-time cardiac monitoring, is the primary growth driver.
- AVITA Medical's Board of Directors has appointed Cary Vance as President and Chief Executive Officer effective immediately, following his successful six-month tenure as Interim CEO since October 2025. - The appointment follows a thorough search process conducted with an international executive search firm, with the Board unanimously concluding that Vance is the right leader for the company's growth period. - Vance brings 30 years of healthcare executive experience and has demonstrated decisive leadership in stabilizing the business, sharpening strategic focus, and rebuilding confidence among employees, customers, and shareholders. - Jan Stern Reed has been elected as Chair of the AVITA Medical Board, bringing over 35 years of legal and business management experience in the healthcare industry.
- GE HealthCare has dosed the first patient in its Phase 2/3 LUMINA trial for mangaciclanol, a manganese-based MRI contrast agent with FDA Fast Track designation. - The investigational agent could offer an alternative to gadolinium-based contrast agents, addressing concerns about retention, supply security, and environmental impact. - Mangaciclanol demonstrates comparable relaxivity to market-leading gadolinium agents with early clinical images suggesting similar diagnostic capability. - The global market includes approximately 65 million gadolinium contrast procedures annually, representing significant commercial potential for this novel imaging agent.
- GE HealthCare has secured FDA 510(k) clearance for View, a cloud-native diagnostic viewer within its Genesis Radiology Workspace designed to streamline radiological workflows. - The solution addresses a critical inefficiency where radiologists spend up to 44% of their time on non-interpretive tasks such as interface navigation and waiting for images to load. - View offers 2D and 3D visualization with AI-enabled tools, allowing radiologists to work from virtually anywhere with full diagnostic confidence and access to advanced visualization applications. - The zero-footprint viewer aims to transform radiology workflows by removing traditional infrastructure barriers and enabling faster collaboration across care teams.
